去纤维钠（去纤苷）用法用量

(Defibrinoside) has anti-thrombotic, fibrinolytic, anti-ischemic, and anti-infective effects in vivo and in vitro. Defibrotide sodium is an adenosine receptor agonist with multiple effects. The adenosine A1/A2 receptors of endothelial cells are involved in the regulation of endothelial cells and the response of endothelial cells to injury. Defibrotide sodium can act on these receptors to produce a variety of downstream effects. Defibrinated sodium can also reduce the expression of cell adhesion molecules on the surface of endothelial cells, thereby reducing the adhesion of leukocytes to vascular endothelial cells and reducing the inflammatory damage of endothelial cells. In addition, defibrinated sodium can also promote the release of prostaglandin 12 (PGl2) and prostaglandin E2 (PGE2), thereby causing vasodilation, inhibiting platelet aggregation, and reducing ischemic damage.

In order to ensure that the efficacy of the drug is fully exerted, it is very important for patients to understand and master the correct usage and dosage of defibrination sodium (defibrinoside). So, how to use defibrotide sodium (defibrinoside)?

Defibrotide sodium (defibrinoside) can be administered via intravenous injection or oral administration. Intravenous administration can quickly reach the maximum blood concentration Cmax, and oral administration can reach Cmax 30 minutes later. In view of factors such as hydrolytic inactivation of digestive tract nucleases, intestinal absorption efficiency of defibrinoside, and liver first-pass effect, the oral bioavailability is only 58~71%. The half-life of defibrinated sodium for injection is about 10 to 30 minutes, while the elimination of defibrinated sodium for oral administration takes several hours and is mainly excreted through urine and feces. The advantage of oral administration is that defibrinated sodium can exert its effect slowly and continuously.

In general, the recommended dose of defibrotide sodium for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Give (Defitelio) for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue defibrotide until resolution of VOD.

Recommended hot articles: /newsDetail/78684.html